Answer 1 is incorrect.  2% chose the answer, Afrezza inhaled insulin. Insulin helps lower blood glucose levels, which contributes to improved overall vessel health. However, there are currently no specific studies supporting the use of Afrezza as a first-line treatment strategy for managing chronic kidney disease.

Answer 2 is correct. 63.39% of you chose this answer the best answer, semaglutide (Ozempic). GREAT JOB!  According to the 2025 ADA Standards, “a recent clinical trial suggests that the GLP-1 RA semaglutide has a beneficial effect on CVD, mortality, and kidney outcomes among people with Chronic Kidney Disease (CKD), leading to the recommendation that semaglutide can be used as another first-line agent for people with CKD.”

Answer 3 is incorrect. About 12.34% of respondents chose Amylin (Pramlintide). Amylin is an injected hormone mimetic that helps lower blood glucose levels. However, there are currently no specific studies supporting the use of Amylin as a first-line treatment strategy for managing chronic kidney disease.

Finally, Answer 4 is incorrect. 22.38% chose this answer, Sitagliptin (Januvia). Sitagliptin helps lower A1C levels by 0.5-0.7%.  However, there are currently no specific studies supporting the use of sitagliptin as a first-line treatment strategy for managing chronic kidney disease.

We hope you appreciate this week’s rationale! Thank you so much for taking the time to answer our Question of the Week and participate in this fun learning activity!